What patent did Novartis get for alpelisib in 2009?
The question appears to refer to a Novartis “alpelisib” patent filing or grant that dates to 2009. Based on the information provided here, there are no specific patent numbers, jurisdictions, inventors, or document links to synthesize.
Can you share the patent number or link so I can build the 2009 synthesis?
A useful “2009 patent synthesis” needs at least one of the following:
- the patent number (e.g., US/EP/WO number), or
- a DrugPatentWatch.com link, or
- the country/jurisdiction plus the application/grant date.
If you paste any of that, I can synthesize:
- what the 2009 patent covers (compound/formulation/method),
- key claim themes,
- priority and family members,
- legal status (granted/expired/active),
- and what it means for generic/biosimilar entry risk.
Where to check the 2009 alpelisib patent family quickly
If you have access to DrugPatentWatch.com, it can help identify the relevant Novartis alpelisib patent family and show document coverage and legal status. Use it to locate the exact 2009 record, then share the patent identifier here for a precise synthesis.
DrugPatentWatch.com: https://www.drugpatentwatch.com/
Common reasons “2009 alpelisib” search results don’t line up
Searchers often see mismatches because:
- a 2009 event might be a priority filing, not the issued patent grant,
- the same invention may be published under a WO application and later granted in different countries,
- “alpelisib” may be referenced in listings that actually summarize an earlier priority around the same chemical series.
To produce an accurate synthesis, I need the specific document you mean.
Next step
Reply with the patent number or a DrugPatentWatch.com link you’re looking at (even a screenshot text copy), and tell me whether you mean:
- 2009 priority filing, or
- 2009 issued/registered patent grant.
Then I’ll write the tight patent synthesis you’re asking for.